Back to News
Market Impact: 0.15

Guru Fundamental Report for TMO

TMONDAQ
Company FundamentalsAnalyst InsightsMarket Technicals & FlowsDerivatives & VolatilityCapital Returns (Dividends / Buybacks)Healthcare & Biotech
Guru Fundamental Report for TMO

Validea's guru fundamental report on Thermo Fisher Scientific (TMO) highlights its highest rating under Pim van Vliet's Multi-Factor Investor model, which prioritizes low volatility, strong momentum, and high net payout yields. TMO, a large-cap growth stock, achieved a 68% rating, indicating some interest but below the 80% threshold for strong interest, notably receiving a "Fail" on its final rank within the strategy despite passing market cap and standard deviation criteria. This suggests a mixed fundamental profile for TMO within a low-volatility, factor-based investment framework.

Analysis

According to a Validea fundamental report, Thermo Fisher Scientific (TMO) receives a mixed assessment based on Pim van Vliet's Multi-Factor Investor model, which prioritizes low volatility, strong momentum, and high net payout yields. While TMO is highlighted as the highest-rated stock by this specific model, it only achieves a score of 68%, falling short of the 80% threshold that indicates strategic interest and ultimately resulting in a "Fail" on its final rank. The analysis reveals that TMO successfully passes the criteria for large market capitalization and low standard deviation, aligning with the core low-risk tenet of the strategy. However, its performance is diluted by "Neutral" ratings on two key factors: its "Twelve Minus One Momentum" and its "Net Payout Yield." This indicates that while the stock exhibits desirable low-volatility characteristics, it currently lacks the strong price momentum and robust shareholder return profile required to qualify as a top-tier candidate under this quantitative framework, a conclusion supported by the report's moderately negative sentiment score of -0.3.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo